- THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH EGFR <30 ML/MIN/1.73M2: FINDINGS FROM THE DAPA-CKD TRIALChertow, G.; Vart, P.; Jongs, N.; Toto, R.; Gorriz, J. L.; Hou, F. F.; Mcmurray, J.; Correa-Rotter, R.; Rossing, P.; Sjostrom, C. D.; Stefansson, B. V.; Langkilde, A. M.; Wheeler, D. C.; Heerspink, H. J. L.
- The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failureHeerspink, J. L.; Wheeler, D. C.; Vart, P.; Jongs, N.; Hou, F. F.; Langkilde, A. M.; Correa-Rotter, R.; Rossing, P.; Sjostrom, C. D.; Toto, R. D.; Chertow, G. M.; Stefansson, B. V.; McMurray, J. J. V.
- Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEFZhao, Li-Min; Ding, Liang-Liang; Zhan, Ze-Lin; Qiu, Mei*Cardiovascular Drugs and Therapy, 2021, 35(5): 1077-1078.被引 2
会议论文
DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL
1被引15阅读
